Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2022 | The role of myeloid-derived suppressor cells in breast cancer

Céline Blaye • 4 May 2022
ESMO Breast 2022
Breast Cancer

Historically, breast cancer has been described as immunologically cold. However, Céline Blaye, MD, University of Bordeaux, Bordeaux, France, describes findings of myeloid-derived suppressor cells within the breast cancer environment, which play a significant role in breast cancer immunosuppression. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.

More from Céline Blaye

1:23
Exploring myeloid cells to reverse the hormone-mediated microenvironemnt of luminal breast cancer
Céline Blaye • 4 May 2022
0:27
Immunotherapy insights from ESMO Breast 2022
Céline Blaye • 4 May 2022
1:22
Immunological signatures to predict outcomes in patients with TNBC
Céline Blaye • 4 May 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals